Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIX NASDAQ:CLLS NASDAQ:IRD NASDAQ:LRMR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$2.48-5.3%$2.79$2.44▼$5.46$87.84M0.59102,168 shs110,172 shsCLLSCellectis$3.06-2.9%$3.69$1.33▼$5.48$316.07M2.8640,791 shs46,987 shsIRDOpus Genetics$4.03-13.1%$4.83$0.90▼$5.81$377.67M0.56918,976 shs1.02 million shsLRMRLarimar Therapeutics$3.17-3.6%$4.18$2.22▼$6.42$341.77M0.831.68 million shs1.24 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+3.97%-2.96%-12.67%-8.07%-6.09%CLLSCellectis+1.94%-13.22%-16.22%-11.52%+120.28%IRDOpus Genetics+10.48%+10.48%-10.77%-5.11%+368.69%LRMRLarimar Therapeutics+2.81%-5.73%-17.96%-36.97%+34.29%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIXAnixa Biosciences$2.48-5.3%$2.79$2.44▼$5.46$87.84M0.59102,168 shs110,172 shsCLLSCellectis$3.06-2.9%$3.69$1.33▼$5.48$316.07M2.8640,791 shs46,987 shsIRDOpus Genetics$4.03-13.1%$4.83$0.90▼$5.81$377.67M0.56918,976 shs1.02 million shsLRMRLarimar Therapeutics$3.17-3.6%$4.18$2.22▼$6.42$341.77M0.831.68 million shs1.24 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIXAnixa Biosciences+3.97%-2.96%-12.67%-8.07%-6.09%CLLSCellectis+1.94%-13.22%-16.22%-11.52%+120.28%IRDOpus Genetics+10.48%+10.48%-10.77%-5.11%+368.69%LRMRLarimar Therapeutics+2.81%-5.73%-17.96%-36.97%+34.29%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIXAnixa Biosciences 2.25Hold$8.50242.74% UpsideCLLSCellectis 2.83Moderate Buy$7.00128.76% UpsideIRDOpus Genetics 2.88Moderate Buy$10.67164.68% UpsideLRMRLarimar Therapeutics 3.09Buy$15.29382.20% UpsideCurrent Analyst Ratings BreakdownLatest ANIX, LRMR, IRD, and CLLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026IRDOpus Genetics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/4/2026IRDOpus Genetics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$16.005/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/28/2026CLLSCellectis BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/27/2026LRMRLarimar Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$9.005/21/2026IRDOpus Genetics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.005/18/2026LRMRLarimar Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$13.00 ➝ $12.005/13/2026IRDOpus Genetics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$12.00 ➝ $11.005/12/2026IRDOpus Genetics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/30/2026IRDOpus Genetics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy4/28/2026IRDOpus Genetics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIXAnixa BiosciencesN/AN/AN/AN/A$0.42 per shareN/ACLLSCellectis$68.07M4.51N/AN/A$0.76 per share4.03IRDOpus Genetics$11.98M27.37N/AN/A$0.22 per share18.32LRMRLarimar TherapeuticsN/AN/AN/AN/A$0.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIXAnixa Biosciences-$10.93M-$0.33N/AN/AN/AN/A-70.95%-62.53%6/10/2026 (Estimated)CLLSCellectis-$67.59M-$0.67N/AN/AN/A-89.51%-80.66%-20.51%7/30/2026 (Estimated)IRDOpus Genetics-$49.59M-$1.33N/AN/AN/A-892.36%-338.88%-191.21%8/12/2026 (Estimated)LRMRLarimar Therapeutics-$165.67M-$2.06N/AN/AN/AN/A-134.14%-96.00%8/13/2026 (Estimated)Latest ANIX, LRMR, IRD, and CLLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/10/2026Q2 2026ANIXAnixa Biosciences-$0.10N/AN/AN/AN/AN/A5/14/2026Q1 2026LRMRLarimar Therapeutics-$0.53-$0.31+$0.22-$0.31N/AN/A5/12/2026Q1 2026IRDOpus Genetics-$0.16-$0.75-$0.59-$0.75$2.93 million$2.16 million5/11/2026Q1 2026CLLSCellectis-$0.2583-$0.18+$0.0783-$0.18$11.04 million$7.55 million3/19/2026Q4 2025CLLSCellectis-$0.10-$0.26-$0.16-$0.26$10.74 million$15.50 million3/19/2026Q4 2025LRMRLarimar Therapeutics-$0.43-$0.73-$0.30-$0.73N/AN/A3/9/2026Q1 2026ANIXAnixa Biosciences-$0.09-$0.08+$0.01-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANIXAnixa BiosciencesN/AN/AN/AN/AN/ACLLSCellectisN/AN/AN/AN/AN/AIRDOpus GeneticsN/AN/AN/AN/AN/ALRMRLarimar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIXAnixa BiosciencesN/A12.1812.18CLLSCellectis1.131.521.52IRDOpus GeneticsN/A7.137.13LRMRLarimar TherapeuticsN/A4.294.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIXAnixa Biosciences29.13%CLLSCellectis63.90%IRDOpus Genetics14.97%LRMRLarimar Therapeutics91.92%Insider OwnershipCompanyInsider OwnershipANIXAnixa Biosciences26.40%CLLSCellectis16.41%IRDOpus Genetics11.70%LRMRLarimar Therapeutics4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIXAnixa Biosciences533.53 million24.68 millionOptionableCLLSCellectis290100.34 million83.87 millionOptionableIRDOpus Genetics1481.40 million71.87 millionN/ALRMRLarimar Therapeutics30103.88 million99.21 millionOptionableANIX, LRMR, IRD, and CLLS HeadlinesRecent News About These CompaniesContrasting Larimar Therapeutics (NASDAQ:LRMR) & Organogenesis (NASDAQ:ORGO)May 31, 2026 | americanbankingnews.comJP Morgan Initiates Coverage of Larimar Therapeutics (LRMR) with Overweight RecommendationMay 28, 2026 | msn.comLarimar Therapeutics Reports First Quarter 2026 Financial and Business UpdateMay 14, 2026 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Stryker (SYK) and Larimar Therapeutics (LRMR)May 2, 2026 | theglobeandmail.comLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich’s AtaxiaApril 30, 2026 | markets.businessinsider.comLarimar Therapeutics Publishes Cross-Species Findings Supporting Skin as a Surrogate for the Measurement of Frataxin in Tissues Clinically Relevant to Friedreich's AtaxiaApril 30, 2026 | globenewswire.comWedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13March 27, 2026 | finance.yahoo.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 19, 2026 | globenewswire.com2 Breakout Stocks to Buy ImmediatelyMarch 8, 2026 | investorplace.comLRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?March 6, 2026 | zacks.comLarimar Therapeutics to Participate in Upcoming Investor Conferences in MarchMarch 4, 2026 | globenewswire.comLarimar Therapeutics price target raised to $12 from $11 at WedbushMarch 4, 2026 | finance.yahoo.comInsider Buying: Larimar Therapeutics (NASDAQ:LRMR) Director Buys $25,000,000.00 in StockMarch 3, 2026 | insidertrades.comLarimar Therapeutics: Deerfield entities buy $25m in stockMarch 3, 2026 | investing.comLarimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed?February 28, 2026 | finance.yahoo.comLarimar Therapeutics stock falls 8% on upsized $100 million offeringFebruary 27, 2026 | in.investing.comWhy Larimar Therapeutics, Inc.’s (LRMR) Stock Is Up 22.49%February 25, 2026 | aaii.comALarimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public OfferingFebruary 25, 2026 | globenewswire.comLarimar Therapeutics Announces Proposed $75 Million Underwritten Public OfferingFebruary 25, 2026 | globenewswire.comLarimar Therapeutics stock surges on FDA breakthrough statusFebruary 24, 2026 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?By Jessica Mitacek | May 12, 2026AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusBy Jessica Mitacek | May 26, 2026Why AST SpaceMobile Is the Bigger Winner of the AT&T, T-Mobile, and Verizon Joint VentureBy Jessica Mitacek | May 20, 2026Fifth Third’s Big Bet Is OnBy Peter Frank | June 4, 2026ANIX, LRMR, IRD, and CLLS Company DescriptionsAnixa Biosciences NASDAQ:ANIX$2.48 -0.14 (-5.34%) As of 04:00 PM EasternAnixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Cellectis NASDAQ:CLLS$3.06 -0.09 (-2.86%) Closing price 04:00 PM EasternExtended Trading$3.06 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Opus Genetics NASDAQ:IRD$4.03 -0.61 (-13.15%) Closing price 04:00 PM EasternExtended Trading$4.04 +0.01 (+0.25%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.Larimar Therapeutics NASDAQ:LRMR$3.17 -0.12 (-3.65%) Closing price 04:00 PM EasternExtended Trading$3.22 +0.04 (+1.42%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
